Project Grant R01HL178513
Award Date
8/1/25
Completion Date
5/31/29
Dollars Obligated
$707K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Yale University is for $477,959 over the period of Sep 2, 2024 to Jun 30, 2027. The project aims to design and pilot test the "Promoting Palliative Care for People with Heart Failure (P3HF)" clinical decision support (CDS) tool. The P3HF CDS will incorporate an automated 1-year mortality risk model for heart failure patients to facilitate referrals to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,604 to Case Western Reserve University to develop and validate a novel transfer volume regression model. This model aims to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project will leverage commonly used, low-cost screening programs to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $429,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Michigan Technological University. The funding supports research to improve patient selection and left ventricular lead placement for cardiac resynchronization therapy (CRT) by integrating analysis of electrical dyssynchrony on ECG and mechanical dyssynchrony on gated SPECT myocardial perfusion imaging. The project aims to use unsupervised...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $392,037 to New York University School of Medicine to conduct research on improving cardiovascular outcomes for patients undergoing non-cardiac surgery. The key objectives of the project are to: 1) survey potential study sites to assess their capacity for patient enrollment and management of patients with myocardial injury after non-cardiac surgery (MINS);...
This Project Grant award of $1,324,607 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to identify key modifiable structures and processes of specialist palliative care delivery that increase the reach and improve end-of-life care quality for people with advanced heart failure. The 4-year project, which began on September 15, 2024, will be conducted by Yale University with a subcontract to the University of Connecticut. The project will...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), will support a $198,936 research project conducted by New York University School of Medicine. The project aims to investigate the impact of restrictive drug coverage policies, such as cost-sharing and prior authorization requirements, on prescribing patterns, medication adherence, and clinical outcomes for patients with heart failure with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $758,862 to Yale University to develop a multi-modality imaging approach for guiding the delivery of therapeutic hydrogels to the heart for prevention of remodeling after myocardial infarction (MI). The project aims to employ hybrid SPECT/CT imaging to non-invasively track markers of inflammation and fibroblast activation, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,674 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effects of guideline-directed medical therapies on mortality in patients with heart failure and mid-range ejection...
This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...